Pfizer, Merck KGaA nab NICE’s favor for Bavencio in Merkel cell carcinoma

After two recent trial flops, Pfizer and Merck KGaA are getting some good news around immuno-oncology contender Bavencio. England’s National Institute for Health and Care Excellence (NICE) has issued a final verdict on reimbursement for the drug in its first indication, Merkel cell carcinoma, and it’s a positive one.Original Article